Document:

Exhibit

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.
DESCRIPTION OF CAPITAL STOCK
 
The following summary description sets forth some of the general terms and provisions of the capital stock. Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of the preferred and common stock, you should refer to the provisions of our amended and restated certificate of incorporation and our bylaws, as amended and restated, each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit.
General
Our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000 shares of preferred stock, par value $0.01 per share. The shares of common stock currently outstanding are fully paid and nonassessable. No shares of preferred stock are currently outstanding.
Common Stock 
Holders of our common stock are entitled to the following rights: 
Voting Rights 
Each share of common stock entitles the holder to one vote with respect to each matter presented to our stockholders on which the holders of common stock are entitled to vote; provided, however, that the Board of Directors may issue or grant shares of common stock that are subject to vesting or forfeiture and that restrict or eliminate voting rights with respect to such shares until any such vesting criteria is satisfied or such forfeiture provisions lapse. Our common stock votes as a single class on all matters relating to the election and removal of directors on our Board of Directors and as provided by law. Holders of our common stock do not have cumulative voting rights. Except as otherwise provided in our amended and restated certificate of incorporation or our bylaws or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter. 
Dividend Rights 
Holders of common stock share equally on a per share basis in any dividend declared by our Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock. 
Liquidation Rights 
In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding at that time, holders of the preferred stock may be entitled to distribution and/or liquidation preferences. In either case, we must pay the applicable distribution to the holders of our preferred stock before we may pay distributions to the holders of our common stock. 
Other Rights 
Our stockholders have no subscription privileges. Our common stock does not entitle its holders to preemptive rights for additional shares. All of the outstanding shares of our common stock are fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock are subject to the rights of the holders of shares of any series of preferred stock which we may issue. 

Preferred Stock 
Our Board of Directors is authorized to provide for the issuance of preferred stock in one or more series and to fix the preferences, powers and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including the dividend rate, conversion rights, voting rights, redemption rights and liquidation preference and to fix the number of shares to be included in any such series without any further vote or action by our stockholders. Any preferred stock so issued may rank senior to our common stock with respect to the payment of dividends or amounts upon liquidation, dissolution or winding up, or both. In addition, any such shares of preferred stock may have class or series voting rights. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of our Company without further action by the stockholders and may adversely affect the voting and other rights of the holders of our common stock.
Anti-takeover Provisions 
Our amended and restated certificate of incorporation and bylaws contain provisions that delay, defer or discourage transactions involving an actual or potential change in control of us or change in our management. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board the power to discourage transactions that some stockholders may favor, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Accordingly, these provisions could adversely affect the price of our common stock. 
Classified Board 
Our amended and restated certificate of incorporation provides that our board is comprised of such number of directors as may be fixed from time to time by resolution of at least a majority of our Board of Directors then in office and that our board is divided into three classes, with one class being elected at each annual meeting of stockholders. Each director serves a three-year term, with expiration staggered according to class. Class I currently consists of three directors, Class II currently consists of three directors, and Class III currently consists of four directors. Our board currently consists of ten directors. 
The classification of our board could make it more difficult for a third-party to acquire, or discourage a third party from seeking to acquire, control of our Company. 
Requirements for Advance Notification of Stockholder Meetings, Nominations and Proposals 
Our bylaws provide that special meetings of the stockholders may be called only upon the request of a majority of our board or upon the request of the chairman of our Board of Directors or our Chief Executive Officer. 
Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board or a committee of our board. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with the advance notice requirements of directors. Our bylaws allow our Board of Directors to adopt such rules and regulations for the conduct of the meetings as they may deem proper, which may be delegated to a chairperson of the meeting and which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our Company. 
No Stockholder Action by Written Consent 
Our amended and restated certificate of incorporation provides that, subject to the rights of any holders of preferred stock to act by written consent instead of a meeting, stockholder action may be taken only at an annual meeting or special meeting of stockholders and may not be taken by written consent instead of a meeting, unless the action to be taken by written consent of stockholders and the taking of this action by written consent has been unanimously approved in advance by our board. Failure to satisfy any of the requirements for a stockholder meeting could delay, prevent or invalidate stockholder action. 

Section 203 of the Delaware General Corporation Law, as amended (“DGCL”) 
Our amended and restated certificate of incorporation provides that the provisions of Section 203 of the DGCL, which relate to business combinations with interested stockholders, do not apply to us. Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a business combination transaction with an interested stockholder (a stockholder who owns more than 15% of our common stock) for a period of three years after the interested stockholder became such unless the transaction fits within an applicable exemption, such as board approval of the business combination or the transaction that resulted in such stockholder becoming an interested stockholder. These provisions would apply even if the business combination could be considered beneficial by some stockholders. Although we have elected to opt out of the statute’s provisions, we could elect to be subject to Section 203 in the future. 
Exclusive Forum 
Our amended and restated certificate of incorporation provides that, unless we consent in writing in advance to the selection of an alternative forum, the Delaware Court of Chancery shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by, or any wrongdoing by, any of our directors, officers or employees to our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation (including as it may be amended from time to time) or our bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits with respect to such claims. However, it is possible that a court could rule that this provision is unenforceable or inapplicable.  
Listing 
Our common stock is listed on the NASDAQ Global Market under the symbol “LNTH.” 
Transfer Agent and Registrar 
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.Exhibit

Exhibit 10.34

*Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Confidential
October 31, 2019
By Email
NTP Radioisotopes (SOC) Ltd.
Building 1700
Pelindaba, R104 Elias Motswaledi Extension
Brits District, North West Province of South Africa
Attention:  Piet Louw
Re:    Volume and Pricing Amendment
Dear Mrs. Tina Eboka:
As we have discussed, Lantheus Medical Imaging, Inc. (“Lantheus”) and NTP Radioisotopes (SOC) Ltd. (“NTP”) are amending the Sales Agreement by and between LMI and NTP, effective as of April 1, 2009 and as amended as of January 1, 2010, April 1, 2011, October 1, 2012 and December 29, 2017 (as amended to date, the “Agreement”) as set forth in this letter agreement (the “Amendment”), effective as of October 1, 2019.  Capitalized terms used, but not defined in this Amendment, have the meanings ascribed in the Agreement.
		
	1.
	Volume Requirements.  

		
	(a)
	Each reference to “**** percent (****%)” in the column entitled “Percentage of Lantheus’ Total Worldwide Requirements of Product” in the table in Section 2.1(b) of the Agreement is hereby replaced with a reference to “**** percent (****%).”  

		
	(b)
	The following provision is added immediately following that table: 

Notwithstanding anything to the contrary in this Agreement, LMI will have the right (exercisable upon **** advance written notice to NTP) to adjust the “Percentage of Lantheus’ Total Worldwide Requirements of Product” set forth in the table above to a higher percentage (i.e. above ****%) or lower percentage (but not below **** percent (****%)) for periods of time no shorter than **** consecutive days.
		
	(c)
	Section 1 of this Amendment serves as an amendment to Section 2.1(b) of the Agreement and supersedes any other agreements between NTP and LMI relating to LMI’s obligations to purchase any particular percentage of its worldwide Product requirements.

		
	2.
	Pricing.  

		
	(a)
	Notwithstanding anything to the contrary in the Agreement (but subject to clauses (b), (c) and (d) of this Amendment), throughout the term of the Agreement, the Invoice Price per Curie will be as follows:

	
											
	Supplier
	2019 Q3
	2019 Q4
	2020 Q1
	2020 Q2
	2020 Q3
	2020 Q4
	2021 Q1
	2021 Q2
	2021 Q3
	2021 Q4

	NTP*
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****

	ANSTO**
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****
	$****

		
	*
	The pricing in this table reflects, for NTP-supplied Product: (i) a **** percent (****%) reduction from the current price effective **** and remaining at that price through ****; (ii) a restoration of the price to the **** level from **** through the remainder of the ****; and (iii) an approximately **** percent (****%) increase effective ****.  Notwithstanding the foregoing, in the event that NTP and the Subcontractor supply to LMI more than **** percent (****%) of LMI’s total worldwide requirements for Product during any of ****, then the pricing of NTP-supplied Product above **** percent (****%) of LMI’s total worldwide requirements for Product for that **** will be $****.

		
	**
	The pricing in this table reflects, for Subcontractor-supplied Product: (i) a **** percent (****%) reduction in price effective from and after ****, (ii) a **** percent (****%) increase, which, however, is contingent upon (and only effective following) ****; (iii) an additional **** percent (****%) increase, which, however, is contingent upon (and only effective following) ****; and (iv) a restoration of the price to the **** level from **** through the remainder of the ****; (v) an approximately **** percent (****%) price increase in **** and another **** percent (****%) price increase in ****, each of which, however, is contingent upon (and only effective following) ****.  Notwithstanding the foregoing, in the event that NTP and the Subcontractor supply to LMI more than **** percent (****%) of LMI’s total worldwide requirements for Product during any of ****, then the pricing of Subcontractor-supplied Product above **** percent (****%) of LMI’s total worldwide requirements for Product for that quarter will be $****.

		
	(b)
	Notwithstanding anything to the contrary in this Agreement, the then-applicable Invoice Price for NTP-supplied Product will revert back to **** for NTP-supplied Product (but only if lower than the then-applicable Invoice Price) on a prospective basis, except for **** where the price will reduce to $**** for orders placed on and after the date on which NTP ****.

		
	(c)
	Notwithstanding anything to the contrary in this Agreement, the then-applicable Invoice Price for Subcontractor-supplied Product will revert back to **** for Subcontractor -supplied Product (but only if lower than the then-applicable Invoice Price) on a prospective basis, for orders placed on and after the date on which Subcontractor ****

		
	(d)
	Section 5.1(b) of the Agreement is hereby deleted in its entirety.

		
	(e)
	Section 2 of this Amendment serves as amendment to Section 5.1(a) of the Agreement and supersedes any other agreements between NTP and LMI relating to Product pricing.

		
	3.
	Term.  Notwithstanding anything to the contrary in the Agreement, the term of the Agreement is extended to and through December 31, 2021.

		
	4.
	Good Faith Negotiations.  Each of the Parties agrees to continue considering and negotiating, in good faith, potential amendments to the remaining provisions of the Agreement (including a ****), with the mutual goal of finalizing and entering into a definitive agreement within **** days after the date of this Amendment.

		
	5.
	Miscellaneous.  Except as expressly amended by this Amendment, the Agreement remains in full force and effect as so amended.

Please confirm NTP’s agreement to this Amendment by countersigning this letter and returning it at your earliest convenience.  

[The remainder of this page is left blank intentionally.]

The Parties, intending to be legally bound, have duly executed this Amendment as of October 1, 2019.
Lantheus:
Lantheus Medical Imaging, Inc.

By:    /s/ Mary Anne Heino    
Name:    Mary Anne Heino    
Title:    President/CEO        

NTP:
NTP Radioisotopes (SOC) Ltd.

By:    /s/ Tina Eboka        
Name:    Tina Eboka        
Title:    Group Managing Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]